Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2438562 | 0.86 | KMT2A (0.50) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL7416001 | 0.84 | ALDH1A1 (0.45) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL4167580 | 0.79 | ALDH1A1 (0.49) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL1128419 | 0.77 | ALDH1A1 (0.47) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL7422643 | 0.76 | ALDH1A1 (0.46) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL9785319 | 0.75 | ALDH1A1 (0.49) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL7424759 | 0.75 | ALDH1A1 (0.45) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL19546678 | 0.75 | ALDH1A1 (0.45) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL7461980 | 0.74 | SLC6A2 (0.48) | ALDH1A1KMT2ASLC6A2LMNAMEN1 | |
| SCHEMBL19546677 | 0.74 | ALDH1A1 (0.44) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115741-B2 | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds | ALEXION PHARMACEUTICALS, INC. | 2006-10-03 | — | — | US | disclosed |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | ALDH1A1 3346/4885TDP1 3579/4885KMT2A 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.